LT2994160T - Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g - Google Patents

Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g

Info

Publication number
LT2994160T
LT2994160T LTEP14730660.9T LT14730660T LT2994160T LT 2994160 T LT2994160 T LT 2994160T LT 14730660 T LT14730660 T LT 14730660T LT 2994160 T LT2994160 T LT 2994160T
Authority
LT
Lithuania
Prior art keywords
alzheimer
treatment
pooled immunoglobulin
subpopulations
disease
Prior art date
Application number
LTEP14730660.9T
Other languages
English (en)
Inventor
David GELMONT
Julia Singer
Sandor Fritsch
Hans-Peter Schwarz
Original Assignee
Baxalta Incorporated
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Incorporated, Baxalta GmbH filed Critical Baxalta Incorporated
Publication of LT2994160T publication Critical patent/LT2994160T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP14730660.9T 2013-05-06 2014-05-05 Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g LT2994160T (lt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361855062P 2013-05-06 2013-05-06
US201361833447P 2013-06-10 2013-06-10
US201361844732P 2013-07-10 2013-07-10
US201361886464P 2013-10-03 2013-10-03
PCT/US2014/036848 WO2014182631A1 (en) 2013-05-06 2014-05-05 Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g

Publications (1)

Publication Number Publication Date
LT2994160T true LT2994160T (lt) 2019-08-26

Family

ID=50943566

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14730660.9T LT2994160T (lt) 2013-05-06 2014-05-05 Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g

Country Status (12)

Country Link
US (3) US20140328856A1 (lt)
EP (2) EP2994160B1 (lt)
JP (1) JP6424210B2 (lt)
AU (4) AU2014262890B2 (lt)
DK (1) DK2994160T3 (lt)
ES (1) ES2740127T3 (lt)
HR (1) HRP20191383T1 (lt)
HU (1) HUE044737T2 (lt)
LT (1) LT2994160T (lt)
PL (1) PL2994160T3 (lt)
PT (1) PT2994160T (lt)
WO (1) WO2014182631A1 (lt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143447A2 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
WO2016033382A1 (en) * 2014-08-27 2016-03-03 Capnia, Inc. Methods for immune globulin administration
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
PT3347002T (pt) * 2015-09-10 2023-07-27 Alzheon Inc Tratamento de doença de alzheimer numa população particular de pacientes
CN114019170A (zh) * 2016-01-20 2022-02-08 基因泰克公司 用于阿尔茨海默氏病的高剂量治疗
SG11201901273TA (en) * 2016-08-18 2019-03-28 Alkahest Inc Blood plasma fractions as a treatment for aging-associated cognitive disorders
CN117899111A (zh) * 2017-04-26 2024-04-19 万能溶剂有限公司 用血浆和血浆制品治疗认知障碍和运动障碍的给药方案
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
AU2018321335B2 (en) 2017-08-22 2025-08-14 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
FI128916B (en) * 2018-02-05 2021-03-15 Vetcare Oy Health-promoting composition and method for its preparation
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
KR102276545B1 (ko) * 2019-09-05 2021-07-15 고려대학교 산학협력단 Ct 영상 기반 부위별 대뇌 피질 수축율 예측 방법 및 장치
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
EP4236988A4 (en) * 2020-10-30 2024-10-30 Rush University Medical Center INTRANASAL IMMUNOTHERAPY FOR THE TREATMENT OF ALZHEIMER'S DISEASE
JP2025506411A (ja) * 2022-02-03 2025-03-11 イーライ リリー アンド カンパニー アルツハイマー病の診断及び治療のための局所タウイメージング

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (lt) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
CA2462682A1 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. The use of gammaglobulin for the treatment of immune-mediated diseases
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
JP2008531560A (ja) 2005-02-23 2008-08-14 アルザ・コーポレーシヨン 中枢神経系への有効成分の鼻内投与
US8852585B2 (en) * 2006-01-30 2014-10-07 Grifols Therapeutics Inc. Method of treatment and prophylaxis of diseases related to amyloid deposition using IgM
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
CN102655853B (zh) 2009-09-17 2015-07-29 巴克斯特卫生保健有限公司 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法
US8622993B2 (en) 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
EP2451348A4 (en) * 2010-04-13 2013-07-31 Baxter Int USE OF THE VENTRICULAR MAGNITUDE RATE IN INTRAVENOUS IMMUNOGLOBULIN TREATMENT OF MORBUS ALZHEIMER
JP2013526518A (ja) * 2010-05-13 2013-06-24 ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション Ｍｃｉおよびアルツハイマー病の処置
EA032336B1 (ru) * 2010-09-17 2019-05-31 Баксалта Инкорпорейтид Стабильная водная иммуноглобулиновая композиция и способ стабилизации иммуноглобулиновой композиции
WO2012099576A1 (en) * 2011-01-18 2012-07-26 Baxter International Inc. Measurement of anti-amyloid antibodies in human blood
US20120251524A1 (en) * 2011-04-01 2012-10-04 Baxter Healthcare S.A. Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease
AU2012311483B2 (en) * 2011-09-24 2016-03-10 Csl Behring Gmbh Combination therapy using immunoglobulin and C1-inhibitor

Also Published As

Publication number Publication date
US20210238267A1 (en) 2021-08-05
US20140328856A1 (en) 2014-11-06
WO2014182631A1 (en) 2014-11-13
JP6424210B2 (ja) 2018-11-14
AU2020257034A1 (en) 2020-11-12
EP2994160A1 (en) 2016-03-16
AU2014262890A1 (en) 2015-11-26
EP2994160B1 (en) 2019-07-03
US20190144530A1 (en) 2019-05-16
HUE044737T2 (hu) 2019-11-28
JP2016518411A (ja) 2016-06-23
AU2014262890B2 (en) 2019-01-31
PL2994160T3 (pl) 2019-10-31
AU2019202459B2 (en) 2020-07-23
ES2740127T3 (es) 2020-02-05
EP3552624A1 (en) 2019-10-16
PT2994160T (pt) 2019-08-07
AU2019202459A1 (en) 2019-05-02
AU2024201051A1 (en) 2024-03-14
HRP20191383T1 (hr) 2020-02-07
DK2994160T3 (da) 2019-08-12

Similar Documents

Publication Publication Date Title
IL268987B (en) System for glaucoma treatment
HUE044737T2 (hu) Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
IL244422A0 (en) Anti-b7-h1 antibodies for treating tumors
EP2945538A4 (en) FITNESS MONITOR
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
EP2951139A4 (en) SYNTHESIS FROM 1,1,2,3-TETRACHLORPROPENE
PT3626270T (pt) Tratamento de doenças cardiovasculares
DK2764881T3 (da) System til medicinsk behandling
HUE067687T2 (hu) Melegsajtolt alkatrészek feldolgozása
LT3007726T (lt) Tautopatijos gydymo būdai
LT2961426T (lt) Centrinės nervų sistemos susirgimų gydymas, per nosį įvedant imunoglobuliną g
HUE044431T2 (hu) Bakteriofág terápia
SG11201505220VA (en) Prevention & treatment of neuropathy
EP2966074A4 (en) morphinan
PT3016977T (pt) Anticorpos humanos anti-il-32
SI2986325T1 (sl) Postopki zdravljenja motenj ciklusa sečnine
GB201302878D0 (en) Modified igG molecules
EP2958454A4 (en) MAGNETOTHERAPEUTIC BAND
DK2976101T3 (da) Behandlingsfremgangsmåde
DK3041506T3 (da) Behandlingsfremgangsmåde
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
HK40032828A (en) Methods for the treatment of mitochondrial disease
GB201321628D0 (en) Treatment of disease
GB201317785D0 (en) Novel healthcare diagnostic method
HRP20190035T1 (hr) Obrada krutina s visokim sadržajem sumpora